GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Terumo Corp (OTCPK:TRUMY) » Definitions » EV-to-EBITDA

TRUMY (Terumo) EV-to-EBITDA : 16.98 (As of May. 28, 2025)


View and export this data going back to 2008. Start your Free Trial

What is Terumo EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Terumo's enterprise value is $27,691 Mil. Terumo's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $1,631 Mil. Therefore, Terumo's EV-to-EBITDA for today is 16.98.

The historical rank and industry rank for Terumo's EV-to-EBITDA or its related term are showing as below:

TRUMY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 13.99   Med: 18.57   Max: 31.18
Current: 16.98

During the past 13 years, the highest EV-to-EBITDA of Terumo was 31.18. The lowest was 13.99. And the median was 18.57.

TRUMY's EV-to-EBITDA is ranked worse than
53.52% of 497 companies
in the Medical Devices & Instruments industry
Industry Median: 15.21 vs TRUMY: 16.98

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-05-28), Terumo's stock price is $18.771. Terumo's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $0.523. Therefore, Terumo's PE Ratio (TTM) for today is 35.89.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Terumo EV-to-EBITDA Historical Data

The historical data trend for Terumo's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Terumo EV-to-EBITDA Chart

Terumo Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.10 16.09 14.21 18.26 16.56

Terumo Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.26 16.46 16.15 17.56 16.56

Competitive Comparison of Terumo's EV-to-EBITDA

For the Medical Instruments & Supplies subindustry, Terumo's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Terumo's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Terumo's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Terumo's EV-to-EBITDA falls into.


;
;

Terumo EV-to-EBITDA Calculation

Terumo's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=27690.850/1631.164
=16.98

Terumo's current Enterprise Value is $27,691 Mil.
Terumo's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,631 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Terumo  (OTCPK:TRUMY) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Terumo's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=18.771/0.523
=35.89

Terumo's share price for today is $18.771.
Terumo's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.523.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Terumo EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Terumo's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Terumo Business Description

Traded in Other Exchanges
Address
2-44-1 Hatagaya, Shibuya-ku, Tokyo, JPN, 151-0072
Started as a clinical thermometer producer in Japan in 1921, Terumo is a comprehensive medical device player with a diversified global revenue. Its product portfolio includes prefilled syringes, insulin patch pumps, neurovascular or cardiac vascular interventional devices, and blood processing systems. As of 2024, the cardiac and vascular business is the largest segment, contributing over 60% of its total revenue. Geographically, North America is the largest region, with 36% of Terumo's revenue.